title: Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3).
abstract: The molecular basis of Glanzmann thrombasthenia (GT) was studied in 40 families from southern India. Of 23 identified mutations (13 in the alphaIIb (ITGA2B) gene and 10 in the beta3 (ITGB3) gene), 20 were novel and three were described previously. Three mutations in the beta3 gene-p.Leu143Trp (Leu117Trp), p.Tyr307Stop (Tyr281Stop), and p.Arg119Gln (Arg93Gln)-were detected in 12, three, and two families, respectively, with definite founder effects observed for the first two mutations. Alternative splicing was predicted in silico for the normal variant and a missense variant of the beta3 gene, and for 10/11 frameshift or nonsense mutations in alphaIIb or beta3. The prediction was confirmed experimentally for a c.2898_2902dupCCCCT mutation in exon 28 of the alphaIIb gene that induced exon skipping. Seven out of nine missense mutations substituted highly conserved amino acids buried in the proteins' cores, predicting structural abnormalities. Among these, a beta3 substitution, p.Cys39Gly (Cys13Gly) was found to cause intracellular degradation of the beta3 subunit, in contrast to previous findings that mutations at Cys435, the partner of Cys13 in a disulfide bond, cause constitutive activation of alphaIIbbeta3. The two patients with a beta3 Arg93Gln mutation had normal clot retraction, consistent with a recent finding that this substitution is associated with normal surface expression of alphaIIbbeta3. In conclusion, this study demonstrates that a variety of mutations account for GT in southern Indian patients, provides new insights into mRNA splicing, and highlights the role of specific amino acids in structure-function correlations of alphaIIbbeta3.
authors.affiliation: Clinical Biochemistry Laboratory, Sourasky Medical Center, Tel Aviv, Israel. hperetz@tasmc.health.gov.il
authors.forename: Hava
authors.initials: H
authors.lastname: Peretz
authors.forename: Nurit
authors.initials: N
authors.lastname: Rosenberg
authors.forename: Meytal
authors.initials: M
authors.lastname: Landau
authors.forename: Saly
authors.initials: S
authors.lastname: Usher
authors.forename: Everette J R
authors.initials: EJ
authors.lastname: Nelson
authors.forename: Ronit
authors.initials: R
authors.lastname: Mor-Cohen
authors.forename: Deborah L
authors.initials: DL
authors.lastname: French
authors.forename: Beau W
authors.initials: BW
authors.lastname: Mitchell
authors.forename: Sukesh C
authors.initials: SC
authors.lastname: Nair
authors.forename: Mammen
authors.initials: M
authors.lastname: Chandy
authors.forename: Barry S
authors.initials: BS
authors.lastname: Coller
authors.forename: Alok
authors.initials: A
authors.lastname: Srivastava
authors.forename: Uri
authors.initials: U
authors.lastname: Seligsohn
mesh_terms: D017398:Alternative Splicing / Q000235:genetics*; D019943:Amino Acid Substitution; D000818:Animals; D006224:Cricetinae; D004252:DNA Mutational Analysis; D019143:Evolution, Molecular; D018703:Founder Effect; D006239:Haplotypes; D006801:Humans; D007194:India; D008958:Models, Molecular; D020125:Mutation, Missense / Q000235:genetics; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000235:genetics*; D017433:Protein Structure, Secondary; D013329:Structure-Activity Relationship; D013915:Thrombasthenia / Q000235:genetics*
chemical_list: D019039:Platelet Glycoprotein GPIIb-IIIa Complex